Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

breakthrough therapy

Navigator – Revolutionize your patient recruitment and retention

Welcome to the new era in patient recruitment and retention

Innovative Trials

- PMLiVE

Shining a Light on Current Topics in Oncology

The Medscape Oncology team will be on the road again, this time in Madrid, Spain for ESMO 2023. This year, the team will be sharing education with a deep impact...

Medscape Education Global

- PMLiVE

Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer

More than 90% of patients with locally advanced disease are not eligible for surgery

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

International study reveals 11 new genes linked to aggressive prostate cancer

Findings from the study could improve treatment options for patients with prostate cancer

- PMLiVE

Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn

The transaction would give Lilly access to experimental radioligand therapies

regeneron headquarters

Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma

The regulator is expected to make a decision on the drug by the end of March 2024

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

New diagnosis pathway has been launched to mark European Myeloma Day

The Myeloma Diagnosis Pathway aims to improve early diagnosis for patients

- PMLiVE

Cancer Research UK partners with French cancer institute

Both organisations will support the global Cancer Grand Challenges initiative

- PMLiVE

Pfizer’s Abrysvo RSV vaccine recommended by US CDC for infants

The recommendation allows Abrysvo to be given to pregnant women from 32 to 36 weeks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links